Roivant Sciences Ltd. (NASDAQ: ROIV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
FOX Nation Taps Vivek Ramaswamy to Host New Series "Truths with Vivek Ramaswamy" Premiering September 22 [Yahoo! Finance]
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at Bank of America Co. from $12.00 to $12.50. They now have a "neutral" rating on the stock.